Chemotherapy augments TRAIL-induced apoptosis in breast cell lines

Cancer Research

Volumn 59, Issue 3, 1999, Pages 734-741

  Keane, Maccon M ^a   Ettenberg, Seth A ^a   Nau, Marion M ^a   Russell, Edward K ^a   Lipkowitz, Stan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; MELPHALAN; METHOTREXATE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CYTOPATHOGENIC EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CASPASE 3; CASPASES; DOXORUBICIN; ENZYME ACTIVATION; FLUOROURACIL; GLUTATHIONE TRANSFERASE; HUMANS; MELPHALAN; MEMBRANE GLYCOPROTEINS; PACLITAXEL; RECOMBINANT FUSION PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033083990     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Kerr, J. F., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
2. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
3. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
4. Keane, M. M., Ettenberg, S. A., Lowrey, G. A., Russell, E. K., and Lipkowitz, S. Fas expression and function in normal and malignant breast cell lines. Cancer Res., 56: 4791-4798, 1996.
5. Bartek, J., Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
6. Runnebaum, I. B., Yee, J. K., Kieback, D. G. Sukumar, S., and Friedmann, T. Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles. Anticancer Res., 14: 1137-1144, 1994.
7. Iwaya, K., Tsuda, H., Fujita, S., Suzuki, M., and Hirohashi, S. Natural state of mutant p53 protein and heat shock protein 70 in breast cancer tissues. Lab Invest., 72: 707-714, 1995.
8. Wang, T. T., and Phang, J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
9. Leek, R. D., Kaklamanis, L. Pezzella, F., Gatter, K. C., and Harris, A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
10. Gee, J. M., Robertson, J. F., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., and Nicholson, R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 59: 619-628, 1994.
11. McCloskey, D. E., Armstrong, D. K., Jackisch, C., and Davidson, N. E. Programmed cell death in human breast cancer cells. Recent Prog. Horm. Res., 51: 493-508, 1996.
12. Hannun, Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood, 89: 1845-1853, 1997.
13. Gruss, H. J. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int. J. Clin. Lab. Res., 26: 143-159, 1996.
14. Ogasawara, J., Watanabe, F. R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.), 364: 806-809, 1993.
15. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., and Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science (Washington DC), 276: 111-113, 1997.
16. Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., and Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (Washington DC), 277: 815-818, 1997.
17. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., and Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (Washington DC), 277: 818-821, 1997.
18. Screaton, G. R., Mongkolsapaya, J., Xu, X. N., Cowper, A. E., McMichael, A. J., and Bell, J. I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol., 7: 693-696, 1997.
19. Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., Timour, M. S., Gerhart, M. J., Schooley, K. A., Smith, C. A., Goodwin, R. G., and Rauch, C. T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBOJ., 16: 5386-5397, 1997.
20. Schneider, P., Bodmer, J. L., Thome, M., Hofmann, K., Holler, N., and Tschopp, J. Characterization of two receptors for TRAIL. FEBS Lett., 416: 329-334, 1997.
21. Wu, G. S., Burns, T. F., McDonald, E. R., III, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and El-Deiry, W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17: 141-143, 1997.
22. MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., and Alnemri, E. S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem., 272: 25417-25420, 1997.
23. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C. Smith, C. A., and Goodwin, R. G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682, 1995.
24. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., and Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690, 1996.
25. Jeremias, I., Herr, I., Boehler, T., and Debatin, K. M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol., 28: 143-152, 1998.
26. Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C. P., DuBose, R. F., Goodwin, R. G., and Smith, C. A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med., 186: 1165-1170, 1997.
27. Gura, T. How TRAIL kills cancer cells, but not normal cells, Science (Washington DC), 277: 768, 1997.
28. Webb, J. L. Effects of more than one inhibitor. Enzymes and Metabolic Inhibitors, Vol. 1, pp. 487-512. New York: Academic Press, 1963.
29. Roth, W., Fontana, A., Trepel, M., Reed, J. C., Dichgans, J., and Weller, M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol. Immunother., 44: 55-63, 1997.
30. Fulda, S., Los, M., Friesen, C., and Debatin, K. M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer, 76: 105-114, 1998.
31. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M. T. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl. Cancer Inst., 89: 783-789, 1997.
32. Mizutani, Y., Okada, Y., Yoshida, O., Fukumoto, M., and Bonavida, B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer (Phila.), 79: 1180-1189, 1997.
33. Nakamura, S., Takeshima, M., Nakamura, Y., Ohtake, S., and Matsuda, T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res., 17: 173-179, 1997.
34. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.
35. Wakahara, Y., Nawa, A., Okamoto, T., Hayakawa, A., Kikkawa, F., Suganama, N., Wakahara, F., and Tomoda, Y. Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncology, 54: 48-54, 1997.
36. Uslu, R., Jewett, A., and Bonavida, B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Gynecol. Oncol., 62: 282-291, 1996.
37. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoplosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
38. Chabner, B. A., and Longo, D. L. (eds.) Cancer Chemotherapy and Biotherapy, Ed. 2, pp. 297-332. Philadelphia: Lippincott-Raveri, 1996.
39. Thornberry, N. A. The caspase family of cysteine proteases. Br. Med. Bull., 53: 478-490, 1997.
40. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature (Lond.), 371: 346-347, 1994.
41. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
42. Widmann, C., Gibson, S., and Johnson, G. L. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J. Biol. Chem., 273: 7141-7147, 1998.
43. Orlinick, J. R., Elkon, K. B., and Chao, M. V. Separate domains of the human fas ligand dictate self-association and receptor binding. J. Biol. Chem., 272: 32221-32229, 1997.
44. Snell, V., Clodi, K., Zhao, S., Goodwin, R., Thomas, E. K., Morris, S. W., Kadin, M. E., Cabanillas, F., Andreeff, M., and Younes, A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol., 99: 618-624, 1997.
45. Mariani, S. M., and Krammer, P. H. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol., 28: 973-982, 1998.
46. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., and Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol., 7: 1003-1006, 1997.
47. Pan, G., Ni, J., Yu, G., Wei, Y. F., and Dixit, V. M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett., 424: 41-45, 1998.
48. Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7: 813-820, 1997.
49. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., and Young, P. R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem., 273: 14363-14367, 1998.
50. Vojtesek, B., and Lane, D. P. Regulation of p53 protein expression in human breast cancer cell lines. J. Cell Sci., 105: 607-612, 1993.
51. Los, M., Herr, I. Friesen, C., Fulda, S., Schulze-Osthoff, K., and Debatin, K. M. Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90: 3118-3129, 1997.
52. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82: 405-414, 1995.
53. Datta, R., Banach, D., Kojima, H., Talanian, R. V., Alnemri, E. S., Wong, W. W., and Kufe, D. W. Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood, 88: 1936-1943, 1996.
54. Ibrado, A. M., Huang, Y., Fang, G., Liu, L., and Bhalla, K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res., 56: 4743-4748, 1996.
55. Ibrado, A. M., Huang, Y., Fang, G., and Bhalla, K. Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ., 7: 1087-1094, 1996.